Latest MHRA Braille Error Notice Shows Why Accessible Product Information Controls Matter
The MHRA has issued a Class 4 Medicines Defect Notification for Fresenius Medical Care Deutschland GmbH’s balance 2.3% glucose, 1.25 mmol/l calcium solution for peritoneal dialysis.
The issue relates to an error in the Braille printed on the outer label. The Braille incorrectly states “CAPD/DPCA 19”, although all other label information and printed data are correct for the listed batches.
The MHRA said there is no product quality issue, the affected batches will not be recalled, and patients can continue using the solution bags from the affected batches. Healthcare professionals were advised to explain the Braille text error to patients who depend solely on Braille for reading medicine packaging where necessary.
For medicines wholesale businesses, this is a useful reminder:
Product information control is part of quality control.
What Happened and Why It Matters
This MHRA notice was not about contamination, potency, stability failure or a defect in the solution itself.
It was about Braille information on the outer label.
That may sound like a small packaging detail, but in medicines supply, information matters. The label, the Braille, the batch details, the leaflet, the supplier notice and the customer communication all support safe and controlled use.
For patients who rely on Braille, accessible product information can be especially important.
So even where the product quality is not affected and there is no recall, the business still needs a controlled way to respond.
A medicines business needs to know:
- Which batches are affected?
- Do we hold any affected stock?
- Has any affected stock already been supplied?
- Who needs to know?
- Does the Responsible Person need visibility?
- Do customers need communication?
- Can the action taken be recorded?
- Can the issue be closed properly?
These are practical quality system questions.
What This Means for Medicines Wholesale Businesses
Medicines wholesale businesses often focus on authorisation, storage, transport and inspection readiness.
Those are essential.
But product information control is also part of a strong GDP quality system.
The MHRA’s GDP guidance says medicines must be obtained from the licensed supply chain and consistently stored, transported and handled under suitable conditions. It also confirms that MHRA inspections check whether manufacturing and distribution sites comply with GMP or GDP.
The same guidance explains that inspections may include review of stock management, storage areas, purchasing and sales functions, transportation arrangements, documents and relevant personnel.
That means information, documents and communication routes matter.
A wholesaler or distribution business may receive:
- MHRA alerts
- Supplier defect notices
- Batch specific information
- Packaging updates
- Labelling corrections
- Patient Information Leaflet updates
- Recall communications
- Customer questions
If these updates are not managed properly, the business may lose visibility and control.
Why Accessible Product Information Matters
Accessible information should not be treated as a side issue.
Where Braille, leaflets or packaging information support patients and healthcare professionals, the business should understand how errors or updates are handled.
A good process should make clear:
- Who receives MHRA and supplier notices?
- Who checks whether affected batches are held?
- Who informs the Responsible Person?
- Who records the issue?
- Who communicates with customers where needed?
- Who checks whether stock instructions have changed?
- Who confirms the issue has been closed?
If these answers are unclear, the business may not be as ready as it thinks.
Why Responsible Person Visibility Matters
The Responsible Person should have visibility where packaging, labelling, product information or defect notifications may affect the GDP quality system.
That does not mean the Responsible Person personally manages every packaging notice.
But it does mean the system should bring important information to the right person early enough.
For example, where a Braille error affects patients who rely on Braille, the business should know whether customer communication is needed and how that communication will be controlled.
That is not just good administration.
It is quality oversight.
What Businesses Should Check Now
If your business is involved in medicines wholesale, WDA(H) readiness, specialist distribution or ongoing GDP compliance, this is a good time to review your accessible product information controls.
Start with these checks:
- Review who receives MHRA alerts and supplier notices.
- Check whether affected batches can be identified quickly.
- Review how Braille, leaflet, carton or label issues are logged.
- Check whether the Responsible Person has visibility of relevant notices.
- Review whether customer communication routes are clear.
- Check whether supplier communications are stored and traceable.
- Review whether SOPs explain what happens when product information is wrong.
- Check whether staff know how to handle packaging or labelling queries.
- Review whether actions are recorded and closed properly.
- Check whether repeated information issues are considered through deviation or CAPA.
These checks are not about creating unnecessary paperwork.
They are about making sure the business can receive, review, communicate and evidence important product information in a controlled way.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support.
This may include:
- GDP quality system review
- Responsible Person / GDP quality support
- Product information control review
- Packaging and labelling process review
- Accessible information process review
- SOP and documentation control review
- Supplier and customer communication review
- Defect notification process review
- WDA(H) application readiness
- Compliance route reviews
- Ongoing compliance support
- Inspection readiness support
Our role is to help businesses understand whether their systems are clear, practical and strong enough before small gaps become bigger risks.
We help clients move forward with clarity, control and confidence.
Final Thought
The latest MHRA Braille error notice is a reminder that product information is part of the medicines supply chain.
Even when product quality is not affected, the business still needs to know what happened, what batches are affected, who needs to know, what needs to be recorded and whether any follow up action is needed.
The strongest businesses do not only control products.
They also control the information that travels with those products.
Need clarity on your product information controls, accessible labelling processes or Responsible Person oversight?
Book a confidential consultation with Stag Global to review your GDP quality system before small information gaps become bigger compliance risks.